AbCellera Q2 net loss widens to $55.4M; revenue drops to $4.1M; new Jazz, Vertex deals

AbCellera Biologics Inc.

Net loss of $55.4M ($0.18/sh) vs $34.7M ($0.12/sh) in Q2 2025; revenue $4.1M vs $17.1M.
Ended quarter with >$565M cash and marketable securities; total liquidity >$675M.
Announced collaborations with Jazz ($84M upfront) and Vertex ($28M upfront) for T-cell engagers.
ABCL635 Phase 2 top-line data expected in August 2026; ABCL575 Phase 1 data expected Q4 2026.
Partner programs progressing: 35 (down from 44 at Dec 2025); 12 molecules in clinic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.